Fennec PEDMARK Study Expansion
Analysis based on 7 articles · First reported Apr 07, 2026 · Last updated Apr 07, 2026
The initiation of new clinical studies for PEDMARK by prominent institutions like University of Arizona Cancer Center, Tampa General Hospital, and City of Hope is a positive development for Fennec Pharmaceuticals. These studies aim to expand the use of PEDMARK to adolescent and young adult (AYA) and adult cancer patients, which could significantly broaden the market opportunity for Fennec Pharmaceuticals' product and potentially lead to label expansion, increasing its revenue potential.
Fennec Pharmaceuticals announced that the University of Arizona Cancer Center is initiating an investigator-sponsored study to evaluate the use of PEDMARK (sodium thiosulfate injection) in adolescent and young adult (AYA) and adult patients with head and neck and testicular cancers receiving cisplatin. This new study, along with two other recently announced institution-led clinical studies by Tampa General Hospital and City of Hope, aims to expand the real-world validation and understanding of PEDMARK's benefits beyond its current approval for pediatric patients. The goal is to support broader clinical adoption of PEDMARK to prevent ototoxicity, or permanent hearing loss, in AYA and adult cancer patients undergoing cisplatin-based treatment, potentially leading to label expansion for Fennec Pharmaceuticals.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard